Effect of Once-Daily Fluticasone Furoate/Vilanterol on 24-Hour Pulmonary Function in Patients With Chronic Obstructive Pulmonary Disease: A Randomized, Three-Way, Incomplete Block, Crossover Study

Clinical Therapeutics

Volumn 34, Issue 8, 2012, Pages

  Boscia, Joseph A ^a   Pudi, Krishna K ^b   Zvarich, Michael T ^c   Sanford, Lisa ^d   Siederer, Sarah K ^d   Crim, Courtney ^c  

^a CU Pharmaceutical Research   (United States)

^b Upstate Pharmaceutical Research   (United States)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

COPD; Efficacy; Fluticasone furoate; Once daily; Vilanterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE FUROATE; GLUCOSE; HYDROCORTISONE; PLACEBO; POTASSIUM; VILANTEROL;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; HYPONATREMIA; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NECK PAIN; POTASSIUM BLOOD LEVEL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SMOKING; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; UPPER RESPIRATORY TRACT INFECTION;

EID: 84864582013     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.06.005     Document Type: Article

References (31)

1. 2011 Guidelines on COPD diagnosis, prevention and management Global Initiative for Chronic Obstructive Lung Disease (GOLD), Accessed June 28, 2012. http://www.goldcopd.org/.
2. Mahler D.A., Wire P., Horstman D., et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 166:1084-1091.
3. Hanania N., Feldman G., Zachgo W., et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in COPD patients: a randomized placebo-controlled trial. Chest 2012 Jan 12, [Epub ahead of print].
4. Calverley P., Pauwels R., Vestbo J., et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361:449-456. TRial of Inhaled STeroids ANd long-acting beta2 agonists study group.
5. Calverley P.M., Boonsawat W., Cseke Z., et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003, 22:912-919.
6. Kardos P., Wencker M., Glaab T. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2007, 175:144-149.
7. Calverley P.M., Anderson J.A., Celli B., et al. Efficacy of salmeterol and fluticasone propionate on mortality in chronic obstructive pulmonary disease: the TORCH survival trial. N Engl J Med 2007, 356:775-789.
8. Tashkin D.P., Rennard S.I., Martin P., et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008, 68:1975-2000.
9. Celli B.R., Thomas N.E., Anderson J.A., et al. Effect of pharmacotherapy on rate of decline of lung function in COPD: results from the TORCH study. Am J Respir Crit Care Med 2008, 178:332-338.
10. Saini S.D., Schoenfeld P., Kaulback K., et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009, 15:e22-e33.
11. Morrison V., Sturton G., Barrett V., et al. Pharmacological characterisation of GW642444, a long-acting ß2-agonist (LABA) with rapid onset and long duration, on isolated large and small human airways. Am J Respir Crit Care Med 2010, 181:A4453.
12. Salter M., Biggadike K., Matthews J.L., et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007, 293:L660-L667.
13. Biggadike K. Fluticasone furoate/fluticasone propionate-different drugs with different properties. Clin Respir J 2011, 5:183-184.
14. Celli B.R., MacNee W. Standards of the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946.
15. Hankinson J.L., Odencrantz J.R., Fedan K.B. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999, 159:179-187.
16. Mahler D., Wells C. Evaluation of clinical methods for rating dyspnea. Chest 1988, 93:580-586.
17. Declaration of Helsinki-ethical principles for medical research involving human subjects. 1964 and updates to 2008 World Medical Association, (supports decl Hel), Accessed June 28, 2012. http://www.wma.net/en/search/index.html?q=helsinki&ue=99members&ul=%2Fen%2F.
18. Guidance for Good Clinical Practice International Conference on Harmonisation (ICH), Accessed June 28, 2012. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf.
19. Brown H., Prescott R. Applied Models in Medicine: Statistics in Practice 2006, John Wiley and Sons Ltd, United Kingdom.
20. Donohue J.F. Minimal clinically important differences in COPD lung function. COPD 2005, 2:111-124.
21. Lötvall J., Bakke P., Bjermer L., et al. Efficacy and safety of four weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial. BMJ Open 2012, 2:e000370.
22. Lötvall J., Bateman E.D., Bleecker E.R., et al. 24h duration of the novel LABA vilanterol trifenatate in asthma patients treated with ICSs. Eur Respir J 2012 Feb 23, [Epub ahead of print].
23. 2 agonist, vilanterol, in persistent asthma: a randomised trial. Resp Med 2012, 106:1110-1115.
24. Bateman E.D., Bleecker E.R., Busse W., et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Resp Med 2012, 106:642-650.
25. Bleecker E.R., Bateman E.D., Busse W., et al. Fluticasone furoate (FF), an inhaled corticosteroid (ICS), is efficacious in asthma patients symptomatic on low doses of ICS therapy. Eur Respir J 2010, 36(Suppl 54):204s.
26. Busse W., Bleecker E.R., Bateman E.D., et al. Fluticasone furoate demonstrates efficacy in asthma patients symptomatic on medium doses of inhaled corticosteroid therapy: a randomised, placebo-controlled trial. Thorax 2012, 67:35-41.
27. Gartlehner G., Hansen R.A., Carson S.S., et al. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis. Ann Fam Med 2006, 4:253-262.
28. Pauwels R.A., Lofdahl C.G., Laitinen L.A., et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999, 340:1948-1953.
29. Burge P.S., Calverley P.M., Jones P.W., et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000, 320:1297-1303.
30. Vestbo J., Sorensen T., Lange P., et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999, 353:1819-1823.
31. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease: Lung Health Study II. N Engl J Med 2000, 343:1902-1909. The Lung Health Study Research Group.